Immunotech Biopharm (HKSE:06978) Other Financing: HK$247.01 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06978 Immunotech Biopharm Ltd HKSE:06978
17 GF Score
Price HK$0.39
! 4 Warning Signs
View Full Analysis

What is Immunotech Biopharm Other Financing?

Immunotech Biopharm HKSE:06978 17 Other Financing is HK$247.01 Mil as of Dec. 2025. GuruFocus rates HKSE:06978 with a GF Score™ of 17/100. The stock has 4 warning signs investors should review.

Immunotech Biopharm's Other Financing for the six months ended in Dec. 2025 was HK$250.63 Mil.

Immunotech Biopharm's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was HK$247.01 Mil.

Immunotech Biopharm Other Financing Historical Data

* Premium members only.

The historical data trend for Immunotech Biopharm's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunotech Biopharm Other Financing Chart

Immunotech Biopharm Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial -4.50 -21.92 -9.32 -8.00 -12.25

Immunotech Biopharm Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.54 -4.15 -3.89 -3.62 250.63
HKSE:06978
17GF Score
Immunotech Biopharm Ltd HKSE:06978
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immunotech Biopharm Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$247.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of HK$247.01 Mil mean?
Immunotech Biopharm (HKSE:06978) has a Other Financing of HK$247.01 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Immunotech Biopharm and its competitors.
Is Immunotech Biopharm's Other Financing too high?
Immunotech Biopharm's current Other Financing is HK$247.01 Mil. Overall, Immunotech Biopharm has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Immunotech Biopharm's Other Financing compare to VRTX and REGN?
Immunotech Biopharm's Other Financing of HK$247.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Immunotech Biopharm and its competitors. Immunotech Biopharm's current Other Financing is HK$247.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunotech Biopharm stock overvalued right now?
Immunotech Biopharm (HKSE:06978) has a current Other Financing of HK$247.01 Mil. The current Other Financing is HK$247.01 Mil. Immunotech Biopharm's overall GF Score™ is 17/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Immunotech Biopharm (HKSE:06978), the current Other Financing is HK$247.01 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Immunotech Biopharm Business Description

Address No.1 Kangding Street, 8th Floor, Block 1, Guosheng Technology Park, Beijing Economic-technological Development Area, Beijing, CHN, 100176
Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series.
17GF Score

Get the complete analysis for HKSE:06978

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.39
Price